Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8
By Sriparna Roy
Sept 27 (Reuters) -The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively damages the lungs and causes restricted airflow.
Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U.S. and other countries.
The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 after the launch for COPD in the country.
Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in revenue in 2030, according to estimates compiled by LSEG. BMO Capital Markets analyst Evan Seigerman in May estimated the drug's peak sales in COPD to reach $2.9 billion in the same year.
COPD, which is the fourth leading cause of death globally, is a lifelong condition that commonly affects cigarette smokers but can also be caused by air pollution and related occupational hazards.
In July, the European Union approved the use of the drug in patients who cannot be helped by standard inhaled treatments for the potentially deadly disease.
In late-stage trials, the drug significantly reduced the moderate or severe exacerbations and also helped to significantly improve lung function, compared to a placebo.
Shares of Regeneron were trading 2.5% higher in morning trade.
Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Sriraj Kalluvila
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
